A new trading day began on Monday, with Day One Biopharmaceuticals Inc (NASDAQ: DAWN) stock price down -3.10% from the previous day of trading, before settling in for the closing price of $12.59. DAWN’s price has ranged from $11.94 to $18.07 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged 67.85%. With a float of $72.64 million, this company’s outstanding shares have now reached $100.81 million.
Let’s look at the performance matrix of the company that is accounted for 155 employees. In terms of profitability, gross margin is 97.37%, operating margin of -206.27%, and the pretax margin is -81.57%.
Day One Biopharmaceuticals Inc (DAWN) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Day One Biopharmaceuticals Inc is 27.97%, while institutional ownership is 81.28%. The most recent insider transaction that took place on Dec 10 ’24, was worth 399,339. In this transaction HEAD OF R&D of this company sold 30,000 shares at a rate of $13.31, taking the stock ownership to the 1,034,015 shares. Before that another transaction happened on Nov 18 ’24, when Company’s CHIEF EXECUTIVE OFFICER sold 10,554 for $13.21, making the entire transaction worth $139,420. This insider now owns 108,377 shares in total.
Day One Biopharmaceuticals Inc (DAWN) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 67.85% per share during the next fiscal year.
Day One Biopharmaceuticals Inc (NASDAQ: DAWN) Trading Performance Indicators
Here are Day One Biopharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 14.55. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 12.07.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.01, a number that is poised to hit -0.46 in the next quarter and is forecasted to reach -1.14 in one year’s time.
Technical Analysis of Day One Biopharmaceuticals Inc (DAWN)
Day One Biopharmaceuticals Inc (NASDAQ: DAWN) saw its 5-day average volume 0.83 million, a negative change from its year-to-date volume of 0.87 million. As of the previous 9 days, the stock’s Stochastic %D was 31.14%. Additionally, its Average True Range was 0.52.
During the past 100 days, Day One Biopharmaceuticals Inc’s (DAWN) raw stochastic average was set at 1.94%, which indicates a significant decrease from 7.56% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 22.41% in the past 14 days, which was lower than the 37.23% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $13.72, while its 200-day Moving Average is $14.28. Nevertheless, the first resistance level for the watch stands at $12.50 in the near term. At $12.81, the stock is likely to face the second major resistance level. The third major resistance level sits at $12.97. If the price goes on to break the first support level at $12.03, it is likely to go to the next support level at $11.87. The third support level lies at $11.56 if the price breaches the second support level.
Day One Biopharmaceuticals Inc (NASDAQ: DAWN) Key Stats
With a market capitalization of 1.23 billion, the company has a total of 100,846K Shares Outstanding. Currently, annual sales are 0 K while annual income is -188,920 K. The company’s previous quarter sales were 93,760 K while its latest quarter income was 37,040 K.
